ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Regulus Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-1.23%
EBIT Growth (5y)
-191.35%
EBIT to Interest (avg)
-30.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.94
Sales to Capital Employed (avg)
0.15
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.24
EV to EBIT
-9.74
EV to EBITDA
-9.81
EV to Capital Employed
120.55
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1237.25%
ROE (Latest)
-68.85%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bearish
No Trend
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
NET PROFIT(HY)
Higher at USD -22.43 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
CASH AND EQV(HY)
Highest at USD 141.27 MM
EPS(Q)
Highest at USD -0.15
-10What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -43.54 MM
NET PROFIT(HY)
At USD -22.43 MM has Grown at -35.66%
Here's what is working for Regulus Therapeutics, Inc.
Net Profit
Higher at USD -22.43 MM
than preceding 12 month period ended Mar 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.15
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 141.27 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Regulus Therapeutics, Inc.
Net Profit
At USD -22.43 MM has Grown at -35.66%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Cash Flow
Lowest at USD -43.54 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
